Uveitis treatment shows promise

Article

Curcumin-based treatment Norflo, has been shown to alleviate the symptoms of anterior uveitis in a recent study published in Clinical Ophthalmology, indicating a potential role for the anti-inflammatory treatment curcumin in eye inflammatory and degenerative conditions.

Curcumin-based treatment Norflo, has been shown to alleviate the symptoms of anterior uveitis in a recent study published in Clinical Ophthalmology, indicating a potential role for the anti-inflammatory treatment curcumin in eye inflammatory and degenerative conditions.

The study conducted by Dr Pia Allegri et al., examined the efficacy of an adjunctive-to-traditional treatment with Norflo tablets (curcumin-phosphatidylcholine complex; Meriva) in recurrent anterior uveitis of different aetiologies.

Norflo, administered twice daily, was found to be well-tolerated, reducing the symptoms of anterior uveitis of different origins in more than 80% of the 106 patients treated. Thus the study indicated that the treatment can play an important role in the adjunctive therapy of recurrent anterior uveitis of various origins.

For further details please click here

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.